Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTPO + Dexamethasone vs High-dose Dexamethasone in Primary ITP
NCT01734044Phase 3Completed
- Sponsor
- Shandong University
- Start
- Jul 2012
- Primary completion
- Jul 2014
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of recombinant human thrombopoietin in primary immune thrombocytopenia (ITP) (2 arms), sponsored by Shandong University. Primary endpoints: Evaluation of platelet response at 1 year and Evaluation of platelet response (R) at 1 year. Started Jul 2012; status: completed.
02
Drugs
recombinant human thrombopoietin
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT01734044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01734044.